Q-omics provides the consensus-scored C20orf194 profile across patient tissues and cancer cell-line models. C20orf194 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, C20orf194 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, C20orf194 protein abundance shows 22,675 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, COAD, and GBM as cancer lineages where C20orf194 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C20orf194 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C20orf194 survival associations across molecular data types. C20orf194 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C20orf194 RNA expression–survival associations across cancer types. High C20orf194 expression shows unfavorable associations in LUSC, but favorable associations in KIRC, SKCM, UCS, LUAD and THYM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for C20orf194 RNA expression.
This table summarizes C20orf194 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for C20orf194. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C20orf194 shows lower tumor expression in COAD, LUAD, BLCA, KIRC and KICH and higher tumor expression in HNSC. The COAD box plot shows higher C20orf194 RNA expression in normal versus tumor tissue (log2 FC = −1.125, t-test p < 0.001).
This table shows molecular features associated with C20orf194 in patient tissues and cancer cell lines. In patient samples, C20orf194 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, C20orf194 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and UPPER_AERODIGESTIVE_TRACT.
